Boosting endocannabinoids in tissue reduced heightened pain in a depression mouse model | Research

The takeaway

In mice with interferon-alpha-induced depression, inflammatory pain was heightened and endocannabinoid levels changed in pain-processing brain regions, while drugs that boost local endocannabinoid levels reduced the excessive pain response.

People interested in the pain-depression connection, endocannabinoid research, or why cannabis might help some pain conditions.

Endocannabinoid-boosting drugs reduced heightened pain only in depressed mice, not healthy ones

What the researchers found

Repeated IFN-alpha treatment increased formalin-evoked pain behavior in mice. Endocannabinoid levels (2-AG and AEA) rose in pain-processing brain regions (PAG and RVM) after formalin in IFN-alpha-treated mice. Local administration of endocannabinoid-boosting drugs (PF3845 and MJN110) reduced the heightened pain response in depressed but not control mice.

Why it matters

Depression and chronic pain frequently co-occur, and this study reveals the endocannabinoid system as a mechanistic link. The finding that boosting endocannabinoids specifically helped the heightened pain in depression suggests targeted therapeutic potential for this common comorbidity.

The numbers in context

IFN-alpha increased formalin-evoked pain without affecting hot plate responses. 2-AG levels increased in PAG and RVM; AEA increased in RVM. PF3845 (AEA booster) and MJN110 (2-AG booster) at 1 microgram/10 microliters reduced hyperalgesia only in IFN-alpha-treated mice.

How the study worked

Male C57/Bl6 mice received repeated IFN-alpha (8000 IU/g/day) to induce depressive-like behavior confirmed by forced swim and sucrose preference tests. Pain responses were measured via hot plate and formalin tests, with endocannabinoid levels measured in brain and peripheral tissues by LC-MS/MS.

What this study cannot tell us

Mouse model with pharmacologically induced depression (IFN-alpha), which may not fully represent human depression. Only male mice used. Only inflammatory pain was studied, not other pain types. Peripheral drug administration only.

How to read the evidence

Preliminary: well-designed animal study with multiple outcome measures, but mouse model only.

When this study was published

Published in 2019.

The bigger picture

Many patients with depression also experience amplified pain, and current treatments address each condition separately. Understanding that the endocannabinoid system mediates the pain-depression overlap could lead to single treatments that address both simultaneously.

Questions still open

Would systemic endocannabinoid-boosting drugs also reduce depression-associated hyperalgesia? Do these findings extend to depression models beyond IFN-alpha? Could FAAH or MAGL inhibitors help patients with comorbid depression and chronic pain?

Common questions

Why does depression make pain worse?

This study suggests the endocannabinoid system plays a role. In depressed mice, endocannabinoid levels changed in brain pain-processing centers, and inflammatory pain responses were amplified. Boosting local endocannabinoids reversed this amplification.

Could cannabinoids help with both depression and pain?

This animal study provides mechanistic support for the idea. Drugs that boosted local endocannabinoid levels reduced pain amplification specifically in depressed mice, suggesting the endocannabinoid system mediates the depression-pain overlap.

Read the original research

Endocannabinoid modulation of inflammatory hyperalgesia in the IFN-α mouse model of depression.

Brain, behavior, and immunity, 82, 372-381

View on PubMed ↗Publisher’s paper ↗

Citation

Fitzgibbon, Marie; Kerr, Daniel M; Henry, Rebecca J; Finn, David P; Roche, Michelle. (2019). Endocannabinoid modulation of inflammatory hyperalgesia in the IFN-α mouse model of depression.. Brain, behavior, and immunity, 82, 372-381. https://doi.org/10.1016/j.bbi.2019.09.006